Ulrike Graefe‐Mody

Author

Ulrike Graefe‐Mody

Boehringer Ingelheim (Germany)

Also Known As

U Graefe-Mody, U. Graefe-Mody, U. Graefe‐Mody, Ulrike Graefe-Mody, Ulrike Graefe‐Mody, Ulrike U. Graefe-Mody

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Centre for Human Genetics Lund University Leiden University Medical Center University of Copenhagen

About

Ulrike Graefe‐Mody is an author at Boehringer Ingelheim (Germany) specializing in pharmacology, medicine, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	546
2	Public Health	2	2	48
3	Health Sciences	1	1	23
4	Biochemistry	1	1	46
5	Clinical Nutrition	1	1	23

Ulrike Graefe‐Mody

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
A reference map of potential determinants for the human serum metabolome Noam Bar, Tal Korem, Omer Weissbrod, Nature Reference MapHuman Serum MetabolomeMedicinePhysiologyBioanalysis	2020	427
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin <sup>*</sup> Ulrike Graefe‐Mody, Christian Friedrich, Andreas Port, Diabetes Obesity and Metabolism	2011	185
Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes Thomas Först, B. Uhlig‐Laske, Arne Ring, Diabetic Medicine	2010	128
Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models Rosa Lundbye Allesøe, Agnete Troen Lundgaard, Ricardo Hernández Medina, Nature Biotechnology	2023	95
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials Adem Y. Dawed, Andrea Mari, Andrew Brown, The Lancet Diabetes & Endocrinology	2022	92
Pharmacokinetics of linagliptin in subjects with hepatic impairment Ulrike Graefe‐Mody, Peter W. Rose, Silke Retlich, British Journal of Clinical Pharmacology	2012	76
Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i> ) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i> ) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study Adem Y. Dawed, Kaixin Zhou, Nienke van Leeuwen, Diabetes Care	2019	61
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin Heike Zimdahl, Carina Ittrich, Ulrike Graefe‐Mody, Diabetologia	2014	60
The oral DPP‐4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus Thomas Först, B. Uhlig‐Laske, Arne Ring, Diabetes Obesity and Metabolism	2011	55
Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus T. Rauch, Ulrike Graefe‐Mody, Carolyn F. Deacon, Diabetes Therapy	2012	51

Page 1